Simulations Plus, Inc. (SLP)
NASDAQHealth CareSoftware - ApplicationSnapshot 2026-11-04
$18.500.00%
Close 2026-10-06 · 1-day change
NASDAQHealth CareSoftware - ApplicationSnapshot 2026-11-04
Research Workspace
Put SLP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 0% on a typical day and fell roughly 45% in its worst 12-month stretch.
View RiskSLP's FDA adoption expansion has to keep compounding to justify the price. Revenue grew 7% year over year in the latest quarter. The stock trades at 21 times earnings. The peer median sits at 21 times earnings. The price reflects less growth than we forecast. Our model puts the next-quarter miss near 28%. Peer multiples imply a price about 1% above where it trades. This read is provisional.
Trailing returns as of 2026-10-06. SLP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering SLP (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SLP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SLP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put SLP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Expansion supports growth and aligns with management's objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-06. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Acquisition enhances growth potential and strategic alignment.